At a glance
ClinicalIndex Comparison RecordN/ACompleted· 61 enrolled
Drug / intervention
Bifidobacterium breve Bif195 +1 moredietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Effects of Bifidobacterium Breve Bif195 for Diarrhea-predominant Irritable Bowel Syndrome: a Double-blind, Randomized, Placebo-controlled Study
In Brief
A clinical study evaluating Bifidobacterium breve Bif195 and Placebo for Irritable Bowel Syndrome. Completed, enrolled 61 participants across 2 sites.
Detailed Summary
The purpose of this study is to investigate if the probiotic Bifidobacterium breve Bif195 (Bif195) will result in improvement in clinical outcome in patients with diarrhea-predominant irritable bowel syndrome (IBS).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIrritable Bowel Syndrome
CountriesDenmark
CollaboratorsChr Hansen
Timeline
N/ACompletedFinished
20222023202420252026
First PostedMar 2021
Enrollment StartApr 2021
Primary CompletionMay 2023
TodayJul 2026
First PostedMar 22, 2021
Enrollment StartApr 16, 2021
Primary CompletionMay 9, 2023
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 5.3 years ago
Interventions
Bifidobacterium breve Bif195dietary
1 capsule daily for 8 weeks
Placebodietary
1 capsule daily for 8 weeks